secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001193125-26-114306
Event type: litigation
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst bench trial for FIRDAPSE patents delayed from March 23 to May 18, 2026
-------------------------------------------------------------------------------

- District of New Jersey order delays start of bench trial to May 18, 2026, originally March 23, 2026.
- Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring 2032, 2034, and 2037.
- Litigation is with Hetero USA, Inc. over Catalyst's proprietary drug FIRDAPSE patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526114306/0001193125-26-114306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526114306/d111324d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-114306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer